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Smart devices and internet-based applications are largely used in allergic rhinitis and may help to 163 
address some unmet needs. However, these new tools need to first of all be tested for privacy rules, 164 
acceptability, usability and cost-effectiveness. Secondly, they should be evaluated in the frame of the 165 
digital transformation of health, their impact on healthcare delivery and health outcomes. This review 166 
(i) summarizes some existing mHealth apps for allergic rhinitis and reviews those in which testing has167 
been published, (ii) discusses apps that include risk factors of allergic rhinitis, (iii) examines the impact 168 
of mHealth apps in phenotype discovery, (iv) provides real-world evidence for care pathways, and 169 
finally (v) discusses mHealth tools enabling the digital transformation of health and care, empowering 170 
citizens and building a healthier society.  171 
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Introduction 219 
Mobile technology has spread rapidly around the globe. Today, it is  estimated that over 5 billion peol  220 
have mobile devices, over half of which are smartphones 221 
(https://www.pewglobal.org/2019/02/05/smartphone-ownership-is-growing-rapidly-around-the-world-but-222 
not-always-equally/).  223 
mHealth (mobile health) is the use of information and communication technology (ICT) for health services 224 
and information transfer (1). mHealth, including apps running on consumer smart devices (i.e., 225 
smartphones and tablets), is becoming increasingly popular and has the potential to profoundly impact 226 
healthcare (2, 3).  The rapid advances in mobile technologies have given rise to new opportunities for the 227 
digital transformation of health and the continued growth in coverage of mobile cellular networks.  The 228 
potential applications and benefits of mHealth are extensive and expanding (4). Implementing mHealth 229 
innovations may also have disruptive consequences (5), so it is important to test applicability in each 230 
individual situation (6). Appropriately identifying and representing stakeholders' interests and viewpoints in 231 
evaluations of mHealth is a critical part of ensuring continued progress and innovation (7). Patient, 232 
caregiver and clinician evaluations and recommendations play an important role in the development of 233 
asthma / AR mHealth tools in supporting the provision of disease management (8).  234 
Smart devices and internet-based applications are already used in allergic rhinitis (AR) and may help to 235 
address some of the unmet needs (2). According to  recent position papers from EAACI (9) and from the 236 
American College of Allergy and Immunology (10), mHealth apps can support the provision of high-237 
quality care to allergic patients, in particular those with AR and/or asthma. This is satisfying for patients 238 
and health care professionals, and has led to a reduction in health care utilization and costs. However, these 239 
new tools need to first of all be tested for privacy rules, acceptability, usability and cost-effectiveness. 240 
Secondly, they should be evaluated in the frame of the digital transformation of health, their impact on241 
healthcare delivery and health outcomes. 242 
1- Strengths and weaknesses of mHealth 243 
Smartphones have radically changed people’s lives. However, despite the global advent of mHealth over 244 
the past two decades, their use and benefits in disease management are unclear. 245 
The benefits of mHealth include paperless information, the potential increase in medication adherence a d 246 
improved monitoring (Table 1). mHealth technology has great potential to increase healthcare quality, 247 
expand access to services, reduce costs, and improve ersonal wellness and public health (11). However, 248 
mHealth may be harmful. Technically, the development of an app is an easy task, which incurs very low 249 
initial investments and does not require in-depth knowledge of the subject itself. The low entry barrier, 250 
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dramatically democratizing the app development enviro ment, also results in a large number of ad-hoc 251 
apps targetting various health concerns of the public. The majority of mHealth apps have neither been 252 
tested on patients nor approved by regulatory organizations such as the US Food and Drug Administration 253 
(FDA) or the European Medicines Agency (EMA). However, many patients rely on these apps in their 254 
everyday lives. 255 
A few weaknesses emerge from the use of mHealth apps that are used in observational studies to assess 256 
real-world evidence for the evaluation of allergy phenotypes or treatments. As for all studies using 257 
participatory data, potential biases include (i) the likelihood of sampling bias, (ii) the difficulty to assess 258 
generalizability of the study, as app users are usually not representative of all patients with AR. In MASK, 259 
it was found that most users report bothersome sympto s (Bedard, submitted) (iii) outcome 260 
misclassification that cannot be assessed, (iv) very little information on patient characteristics, (v) lack of 261 
physicians’ support in the diagnosis of AR, (vi) potential measurement biases due to the so-called 262 
“ informatics illiteracy” of many patients (12), and  (vii) poor adherence to e-Diary compilation, which 263 
makes proving poor adherence to treatment impossible.  264 
One of the major problems with apps is the low adherence to their use. Achieving sufficient mHealth app 265 
engagement and user retention rates is a difficult task. In MASK-air (Mobile Airways Sentinel NetworK), 266 
around half of the patients use the app only once (13).267 
The benefits of mHealth apps are presented in Table 1. 268 
2- Regulatory framework 269 
mHealth raises significant privacy and security challenges in terms of IT privacy, data sharing and consent 270 
management, access control and authentification, confidentiality and anonymity, policies and compliance, 271 
accuracy and data provenance, and security technology (11). 272 
In May 2018, the EU General Data Protection Regulation (GDPR) brought major changes in data privacy 273 
regulation in the EU. The aim of the GDPR is to protect all EU citizens from privacy and data breaches in 274 
today’s data-driven world. It harmonizes data privacy laws across Europe, protects and empowers all EU 275 
citizens’ data privacy and reshapes the way organizations across the region approach data privacy. Thus, all 276 
mHealth apps used in the EU should follow the GDPR. The law applies to personal data (Art. 4 para. 1 no. 277 
1, GDPR) (14). Anonymous or anonymized data should lack identifiability. Anonymization principally 278 
enables the sharing of data in a way that preserves privacy with minimal data loss. Geolocation information 279 
is not only personal data but also has to be considered as an identifier itself (15, 16). Thus, mHealth pps 280 
should follow a geolocation de-anonymization that is rarely found in apps. The k-anonymity method is 281 
acceptable and was found to fulfill the GDPR regulations in AR (17). The GDPR fixes general rules 282 
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applying to any kind of personal data processing as well as specific rules applying to the processing of 283 
special categories of personal data such as health d ta (18).  In May 2020, a new EU law will regulate 284 
mobile technology (Medical Device Regulation, MDR) (19) making its use tightly regulated.  285 
The US regulations were recently reviewed in detail (20). The FDA and the Federal Trade Commission 286 
(FTC) both guide the development and regulation of mHealth devices. Since the recently enacted 287 
amendment to the Twenty-First Century Cures Act - the Food, Drug and Cosmetic Act - certain software 288 
functions are no longer considered to be medical devices (21). Thus, the FDA is now using enforcement 289 
discretion for mHealth apps that do not present risks to patients and consumers. 290 
3- mHealth apps for allergic rhinitis 291 
a. Apps informing on risk factors for allergic rhinitis 292 
Risk factors for exacerbations of AR and asthma include allergen exposure (22), climatic factors (23, 4) 293 
and air pollutants (25). It is therefore of great importance to identify levels of risk factors that cn induce 294 
symptoms in allergic patients. Among these, pollen exposure is the most important for pollen allergic 295 
patients. Therefore, forecasting symptoms of pollen-related AR for the individual patient should improve 296 
disease control and plan pharmacological intervention and/or prevention of exposure.  Besides pollen 297 
diaries, mHealth apps allow an easy and fast documentation of pollen allergy counts (26-28). A study that 298 
analyzed 9 mobile apps delivering pollen information and pollen forecasts found that the quality of pollen 299 
forecasts needs to be improved. It recommended quality control for pollen forecasts to avoid potential h rm 300 
to patients (29).  AR patients could consider the need to avoid the more polluted routes when walking, 301 
biking, or exercising. In many cities, traffic air pollution concentrations decline rapidly at  a few hundred 302 
metres from  roadways, and web-based  applications  can assist  individuals  in  finding  alternative  routes 303 
(30).    304 
There are, however, drawbacks that need to be understood in order to provide better information: (i) The 305 
pollen season does not necessarily correspond to an individual patient’s symptoms (31)  and sub-micronic 306 
particles from pollens can induce severe symptoms such as thunderstorm-induced asthma (32); (ii) The 307 
definition of the pollen season is still unclear (33) although some clarification efforts have been made for 308 
clinical trials (34); (iii) There is a weak correlation between pollen counts and symptoms (35); (iv) 309 
Pollutants and weather conditions can interact with pollens to induce symptoms; (v) Only predictive 310 
models are to be used, not only for forecasting but also for near-real-time analysis (now-casting) since it 311 
takes a few days to count pollens (36). However, these models may need more testing in order to be fully 312 
accepted; (vi) Next-generation pollen monitoring is very promising but its cost prevents a large use (37); 313 
(vii) The onset of individual symptoms (AR, asthma, conjunctivitis) may be associated with different levels 314 
of allergen exposure in patients with different intensities of sensitization and target organ reactivity.  315 
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Google Trends are interesting for complementing pollen counts (38)  but they cannot be readily used as a316 
predictor of the pollen season. However, Google Trends, when used retrospectively, are better correlated 317 
with symptoms than pollen counts (35, 39, 40). 318 
A large number of apps provide information to allergy sufferers regarding pollen counts and/or pollution 319 
data (41). Some examples are given below and in Table 2. 320 
BreezoMeter uses the CAMS pollen predictions and big data analysis to provide a continuous current 321 
condition pollen index (https://breezometer.com/products/pollen-api). However, its validation is not yet available. 322 
Air Matters broadcasts pollen and air quality data in most countries of the world (https://air-matters.com).  323 
The Copernicus Atmosphere Monitoring Service (CAMS), implemented by the European Centre for 324 
Medium-Range Weather Forecasts (ECMWF) on behalf of the European Union, provides forecasts for 325 
birch, olive and grass pollen to allow allergy sufferers in the EU to take preventive measures days before 326 
exposure. (https://atmosphere.copernicus.eu/news-and-media/news cams-helping-allergy-sufferers). CAMS 327 
supports a range of smartphone applications designed to limit exposure to such allergens. One of these is 328 
MetéoPollen for France (https://meteopollen.com). 329 
AccuPollen (http://www.nynjpollen.com) and My Pollen Forecast (https://www.jrustonapps.com/apps/my-pollen-330 
forecast) track pollen counts in the US using forecasts for pollen and climatic data. 331 
The POLLEN app of the European Aeroallergen Network (EAN), maintained by the Medical University of 332 
Vienna (https://www.polleninfo.org), evaluates the pollen situation in European countries using the pollen 333 
counts of EAN and predictions of the SILAM pollen forecasting model (http://silam.fmi.fi).  334 
b. Apps including health data 335 
Many mHealth apps support patients with AR via self-monitoring through an electronic diary (e-Diary), 336 
personalized feedback and/or patient education (42). They aim to improve patient education and self-337 
management on a daily basis but require an evidence-bas d evaluation given that the information provided 338 
on the app stores is limited, in particular for theapps’ validity (43-45). This can be done by evaluating the 339 
effectiveness of the app with the patients’ clinical outcomes (13, 28, 46). For example, children with 340 
moderate-severe seasonal allergic rhinitis, treated with daily mometasone, improved their disease 341 
knowledge thanks to daily informative messages sentby their e-Diary app (42). If patients are seeking a  342 
approach involving the minimal interaction with health care professionals in AR management (47), it is343 
then crucial that the mHealth app is in line with evid nce-based essential self-management principles. A 344 
Mobile app Rating Scale (MARS) instrument (48) - available in Australia - has been used to assess the 345 
mHealth apps for AR (Tan et al, in revision). A ‘patient empowerment index through mobile technology’ 346 
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was recently designed and used to evaluate AR in order to support patients choosing an mHealth app and 347 
physicians recommending it (42).  348 
Most but not all mHealth apps which include clinical d ta are available in English and some are available 349 
in over 15 languages (Table 2). The majority of mHealth apps are freely available on iOS and Android. 350 
However, very few have provided clinical data supporting their validity. mHealth apps for AR include: 351 
• Self-monitoring 352 
• Patient’s feedback 353 
• Patient’s education  354 
• Patient’s empowerment 355 
• Pollen and/or air pollution data 356 
At present (May 2019), some mHealth apps are in non-English languages such as ALK-Allergik 357 
(https://maviedallergik.fr/nos-services), Allergy Track, (https://www.android-logiciels.fr/allergy-track/), 358 
AllyScience (https://allyscience.ch/), e-symptoms (https://www.aha.ch/centre-allergie-suisse), i-pollen 359 
(http://www.gammehumex.fr/lapplication-i-pollen/), Plume Air Report (https://air.plumelabs.com/fr/) and Pollen 360 
App (http://www.pollenstiftung.de/ak). Others in English may be restricted to a limited geographic area such 361 
as Air Rater in Australia (https://airrater.org) or are not available from app stores. 362 
Besides those with a commercial interest (e.g. Sensio Air https://www.wlab.io and Zyrtec AllergyCast 363 
https://www.zyrtec.com/allergy-forecast-tools-apps), there are few mHealth apps with health data on AR (e.g. 364 
AllergyMonitor®, MASK-air® ,WebMD Allergy® https://www.webmd.com/allergy-app and the Austrian 365 
Pollen Information Service www.pollenwarndienst.at) (Table 2). 366 
c. Apps connected with sensors 367 
In asthma, many mHealth apps are connected with sensors for inhalers (20). Such devices do not yet exist 368 
in AR but there are attempts to connect pollution se sors to mHealth apps. Unfortunately, those existing for 369 
asthma appear to be in an exploratory phase and neevalidation. In addition to external sensors, 370 
smartphones and tablets have embedded sensors such as camera, microphone, atmospheric pressure sensor, 371 
accelerometer and GPS. These sensors can be used to provide contextual information for the collected 372 
clinical data. Moreover, using signal processing, data from on board sensors, already available in off-the-373 
shelf devices and used by millions of patients, are being tested as ubiquitous technologies to provide 374 
verified information on cough (49),  lung function (50),  adherence to inhaled treatment (51),  physical 375 
activity parameters and other human behaviours of clinical interest (52).   376 
d- Examples of apps 377 
• AllergyMonitor® (http://www.tpsproduction.com/) 378 
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AllergyMonitor® is an app that has been translated into 10 languages. Its target is to improve allergy 379 
diagnosis by matching trajectories of symptom-medication scores and pollen counts (26, 28, 46, 53, 54). 380 
Furthermore, it enhances shared decision-making by fostering the exchange of information between users 381 
and their health care professionals. The latter can access and view their patients´ recorded data in a back-382 
office, which allows the management of patients´ clini al data and gives a structured overview on the 383 
individual disease management. The data recorded by the user then complete the set of information being 384 
integrated in the back-office in real-time. As users also register the intake of their prescribed medication, 385 
this feature allows the monitoring of compliance which has been shown to effectively increase the 386 
adherence to treatment with nasal corticosteroids an  sublingual allergen-specific immunotherapy. To this 387 
end, the app includes customized lists of over-the-counter and prescribed medications for many countries, 388 
patient-doctor communication via SMS and e-mail, patient alerts for a better knowledge of the disease as 389 
well as reminders for a better adherence to treatment. The potential of data sets generated through 390 
AllergyMonitor® has also been investigated for the short-term prediction of patients´ symptoms with 391 
several symptom and medication scores for rhinitis and asthma.  392 
• MASK (http://www.mask-air.com) 393 
MASK (Mobile Airways Sentinel networK), the Phase 3 ARIA initiative, was instigated to reduce the 394 
global burden of AR and asthma multimorbidity, giving the patient and the health care professional simple 395 
tools to better prevent and manage respiratory allergic diseases. The MASK app (MASK-air®, formerly the 396 
Allergy Diary, freely available for Android and iOS) (55) is the most extensively published mHealth app 397 
for AR. It is an ICT system centred around the patient (13, 55-57) and is operational in 23 countries and 17 398 
languages. It uses a treatment scroll list which inludes all medications customized for each country as well 399 
as visual analogue scales (VASs) to assess rhinitis control and work productivity  (58, 59). MASK-air® is 400 
being combined with data on allergen and pollution exposure (POLLAR) (25). MASK-air® results are 401 
given in Table 3. 402 
MASK is scaled up using the EU European Innovation Partnership on Active and Healthy Ageing (EIP on 403 
AHA) strategy (60). MASK is supported by several EU grants and is a GARD (Global Alliance against 404 
Chronic Respiratory Diseases, WHO (61)) research demonstration project. It is a Good Practice of DG 405 
Santé (62). 406 
 407 
• European Aeroallergen Network Pollen Information Service 408 
The EAN Pollen Information Service (www.polleninfo.org), developed and maintained at the Medical 409 
University of Vienna, provides a pollen assessment and a three-day forecast in co-operation with local and 410 
international institutions. It is available for European countries in over 10 languages. The app includes 411 
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symptoms and treatments. The components and functionali y of the app vary between the countries 412 
depending on the requests of the national pollen observing groups. 413 
The service also takes the user’s pollen diary entries into account and calculates personal burden level. 414 
Allergic symptoms can be documented and compared with the pollen count in the pollen diary. Personal 415 
load, Pollen News, Pollen-Countdown notifications ad  reminder for a doctor´s visit are all available. The 416 
pollen diary was restructured in 2018 and provides information on preventing impaired performance in 417 
everyday life, the time of the highest burden and the ime(s) of being outdoors. The encyclopedia of 418 
allergenic plants is also available to answer question  on allergy.  419 
• e-allergy 420 
The under-recognition of AR is common due to a low evel of public awareness as well as limitations in 421 
access to allergologists (63). AR sufferers often use OTC drugs and self-medicate. mHealth tools 422 
supporting the pre-medical early diagnosis of allergic diseases are important. They use algorithms able to 423 
classify respondents into certain risk groups of AR and asthma. An algorithm was created - with the use of 424 
advanced statistical methods (neural networks) - on ECAP (Epidemiology of the Allergic Diseases in 425 
Poland) data containing both questionnaire answers and medical diagnosis (64). This tool is constantly 426 
being updated. The latest results show a sensitivity for AR in children and adolescents of 0.852 and a 427 
specificity of 0.840 (65). 428 
4- Clinical decision support systems (CDSSs)   429 
A  CDSS is a health information technology (IT) system designed to assist clinicians and other health c re430 
professionals in clinical decision-making. In medicine, CDSSs have become a major topic in artificial 431 
intelligence. According to the National Academy of Medicine (Washington DC) (66), “facilitative clinical 432 
decision support (CDS) is a practical necessity for every clinician in our rapidly-evolving health and 433 
healthcare landscape.” A CDSS can reduce the burden that exponentially-expanding clinical knowledge 434 
and care complexity places on clinicians, other healt  care professionals or patients. CDSs provide 435 
clinicians and other health care professionals with knowledge and person-specific information - 436 
intelligently filtered or presented at appropriate times - to enhance health and health care (67). CDSs can 437 
enhance decision-making through the use of the following tools: (i) computerized alerts and reminders to 438 
health care providers and patients, (ii) clinical guidelines, (iii) focused patient data reports and (iv)439 
diagnostic support (68). Many apps used in AR provide patients with some help for AR control. However, 440 
for this, they should be labelled as CE2A in the EU. Apps that do not provide help can be registered as 441 
CE1. An electronic CDSS (eCDSS) based on MASK now exists in AR and is in the process of validation 442 
(69).  It is not clear whether other tools have been validated as they have not been published. CDSSs may 443 
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also be very useful in stratification strategies and in reporting outcomes in clinical trials such as in Allergen 444 
Immunotherapy (https://www.ncbi.nlm.nih.gov/pubmed/30955224). 445 
5- Potential of mHealth apps for allergy phenotype discovery 446 
Conventionally, phenotypic studies have relied on tradi ional observational designs. Apps provide a new447 
source of information on daily symptoms and the opportunity to discover new phenotypes. Few studies 448 
have been published concerning allergy phenotypes assessed with an app.  449 
A prospective analysis has compared six disease severity scores for AR against pollen counts (53). Many 450 
different and incomparable symptom (medication) scores are used to assess AR control. Disease severity 451 
scores for seasonal AR evaluated by an internet-based platform provide similar results at population level 452 
but are heterogeneous in individual patients.   453 
Multimorbidity in allergic airway diseases is well known (70), but no data has ever existed regarding how 454 
multimorbidity impacts the daily dynamics of specific symptoms, including severity and work. MASK-455 
air® has enabled this investigation in a novel approach of the intra-individual variability of allergic 456 
multimorbidity from day to day (71). AR and rhinoconjunctivitis did not appear to be the same disease. 457 
Moreover, MASK-air®  identified a previously unrecognized extreme pattern of uncontrolled 458 
multimorbidity (uncontrolled rhinitis, conjunctivitis and asthma on the same day) (71). However, mHealth 459 
apps are only tools generating hypotheses and need to be confirmed in classical epidemiologic studies. 460 
Differences between AR alone or associated with conjunctivitis were already known (72) but new studies 461 
carried out following MASK-air® data showed that (i) ocular symptoms are more commn in 462 
polysensitized patients whether or not they have asthma (73), (ii) ocular symptoms are associated withthe 463 
severity of nasal symptoms (74), (iii) ocular symptoms are important to consider in severe asthma (74) and 464 
(iv) the severity of allergic diseases increases with the number of allergic multimorbidities (75). This is the 465 
first time that novel allergic phenotypes have been discovered using an mHealth app and then confirmed 466 
by classical epidemiologic studies. 467 
5- Real world evidence using mHealth in next-generation care 468 
pathways 469 
mHeath apps for a better AR management are growing in umber. However, their usefulness for doctors 470 
and patients is still being debated. Most studies have also highlighted certain shortcomings and limitations, 471 




a. Adherence to treatment 475 
mHealth may help to better understand adherence to treatment and its determinants as well as how to 476 
improve it. In medicine, many mHealth apps are avail ble to support people in taking their medications a d 477 
thus to improve medication adherence (77, 78). However, a meta-analysis found that the majority did not 478 
have many of the desirable features and/or were of low quality (77). A systematic review including 16 479 
RCTs found that mobile phone text messaging approximately doubles the odds of medication adherence, 480 
resulting in a net increase in adherence of 17.8% (78). A Cochrane systemic review of 7 trials in 481 
cardiovascular disease found that, while the results are promising, there is insufficient evidence to draw 482 
conclusions on the effectiveness of text message-bas d interventions for adherence to medications. The 483 
authors suggested that sufficiently powered, high-quality randomised trials are needed, particularly in low- 484 
and middle-income countries (79).  485 
Adherence in randomized control trials (RCTs) is high but does not reflect the real-life situation (29,30) 486 
and alternative measurements of adherence in a real-life setting are needed. The best studies would be 487 
using electronic devices that count and record the drugs taken. However, these devices are still exploratory 488 
and expensive and, as such, they are not currently a viable solution for large studies in AR patients (80) or 489 
individual patients.  A potential palliative solution can be to use the smartphone’s camera to register the 490 
drug uptake. The photo of the drug is then processed by image recognition algorithms to provide verifid 491 
data on adherence to AR treatment during the patient’s daily life. However, there are technical challenges 492 
and limitations to some types of vials and packaging. The automatic detection of progression of use of the 493 
liquid in the vial using computer vision may be of special relevance for sublingual allergen immunotherapy 494 
for which adherence can be a major issue (81). Other approaches already being tested for asthma but not 495 
for AR are mobile direct observation of therapy (82) and multicomponent interventions based on mobile 496 
technologies (83). Although there are already some mH alth apps for AR, there are few studies evaluating 497 
their benefits and impact (76). One study suggested that a short message service (SMS) helps to improve 498 
AR treatment (84). Internet-based telemonitoring using the AllergyMonitor® improved adherence to intra-499 
nasal corticosteroid treatment and disease knowledge among children and adolescents with seasonal AR as 500 
well as adherence to sub-lingual immunotherapy (46). In MASK-air®, a major lack of adherence to 501 
treatment was observed for all medications (85). Auto-medication was very common (12) suggesting that 502 
patients, like allergists when they are allergic (86), do not follow physicians’ prescriptions or guidelines. 503 
b. mHealth in observational studies allowing novel assessment of patients’ 504 
behaviour 505 
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The treatment of AR is complex as many drugs are available in oral and/or topical formulations, and 506 
allergen immunotherapy and avoidance increase the complexity of the management. Many AR guidelines 507 
are evidence-based and have led to a better understanding and management of AR (87-89).  However, 508 
guidelines are mostly based on RCTs, typically undertak n on highly-selected populations and often with 509 
limited/unclear generalizability to routine care contexts.  Large observational implementation studies are 510 
needed to triangulate RCTs as they reflect “real wor d” every-day use and practice more closely than RCTs 511 
in terms of the heterogeneous patient populations included and the variety of medical interventions 512 
assessed. In RCTs, each subject is randomly assigned to a tretm nt or control group, whereas 513 
observational studies examine the possible effect of a treatment on subjects where the investigator has no 514 
control over the experiment and cannot randomize subject allocation (94). However, observational studies 515 
provide clinically relevant information in addition to RCTs. Real-world evidence (RWE) using RCTs and 516 
real-world data (RWD) is becoming increasingly important  in supporting regulatory decisions using 517 
mobile technology (95). 518 
A pilot study in over 2,900 users allowed differentiation between treatments (12) showing that the 519 
assessment of series of consecutive days was useful in understanding treatment patterns. The study showed 520 
that patients did not necessarily use treatment on a daily basis and in a regular way; rather, they appe red to 521 
increase treatment use when their symptom control worsened. Differences in efficacy between medications 522 
were observed. This pilot study was confirmed in almost 9,000 users (96). The studies confirm the 523 
usefulness of mHealth in accessing and assessing everyday use and practice in AR (12). It is hoped that 524 
mHealth apps will increase patient empowerment and improve adherence. 525 
c. Next generation guidelines 526 
The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends 527 
on many factors. GRADE (Grading of Recommendations Assessment, Development and Evaluation) 528 
guidelines have considerably improved AR management. However, there is an increasing trend to use 529 
RWD to inform clinical practice, especially as RCTs are often limited with regards to the applicability of 530 
results. The MACVIA algorithm proposed an AR treatment by a consensus group (97). This simple 531 
algorithm can be used to step-up or step-down AR treatment. Next-generation guidelines for the 532 
pharmacologic treatment of allergic rhinitis (98) were developed using existing GRADE-based guidelines 533 
(87-89), RWD provided by mHealth apps (12, 85, 96) and additive studies (allergen chamber studies (99)) 534 
to refine the MACVIA algorithm (97).  535 
6- mHealth tools enabling the digital transformation of health and 536 
care, empowering citizens and building a healthier society  537 
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The recent report on the State of Health in the EU (State of Health in the EU "Companion Report 2017", 538 
https://ec.europa.eu/health/state)  concluded that rethinking our health and care system  can ensure its 539 
sustainability aiming to continue health promotion, disease prevention and to provide patient-centred care540 
that meets citizens' needs (https://ec.europa.eu/transparency/regdoc/rep/1/2018FR/COM-2018-233-F1-FR-541 
MAIN-PART-1.PDF).  542 
Digital solutions for health and care can increase the well-being of millions of citizens and radically change 543 
health and care services. In its mid-term review on the implementation of the digital single market strategy 544 
(https://ec.europa.eu/transparency/regdoc/rep/1/2017 EN/COM-2017-228-F1-EN-MAIN-PART-1.PDF), 545 
the EU Commission took further action in three areas: 546 
• Citizens' secure access to and sharing of health data across borders. 547 
• Better data to advance research, disease prevention and personalized health and care. 548 
• Digital tools for citizen empowerment and person-cetr d care to allow citizens to assume responsibility 549 
for their health, improve their well-being and quality of care and contribute to sustainable health 550 
systems. By using digital solutions, such as wearables and mHealth apps, citizens can actively engage in 551 
the health promotion and self-management of chronic diseases. Digital tools can potentially disseminate 552 
scientific knowledge in an easily accessible form, so as to help people stay in good health – thus 553 
preventing them from turning into patients. Building on scientific information on risk factors, digital 554 
solutions can be used across all sectors, including education, transport, and urban policies to promote 555 
information and awareness campaigns on healthy lifestyles. Digital tools also enable citizens to provide 556 
feedback and data about their health to their doctors. This can improve the quality of health services and 557 
ultimately people's health and well-being.  558 
Digital tools can also empower patients in the context of the UN sustainable development goals and in 559 
particular regarding those related to sustainability and natural resources (100). Future apps in AR could 560 
consider providing information to promote behavioural changes that could reduce the planetary impacts of 561 
human activity.  562 
In the context of implementing communication on the digital transformation of health and care, DG 563 
SANTE, in collaboration with the newly-established EU Commission Expert Group "Steering Group on 564 
Health Promotion, Disease Prevention and Management of Non-Communicable Diseases” 565 
(https://ec.europa.eu/health/non_communicable_diseases/steeringgroup_promotionprevention_en), 566 
supported the scaling-up and wider implementation of good practices in the field of digitally-enabled, 567 
integrated, person-centred care. MASK was one of the nine Good Practices selected along with chronic 568 
disease and Parkinson’s disease (62). 569 
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8. Global implementation  570 
When mobile technology was initiated, it was thought that it would be used mainly in developed countries. 571 
However, smartphone ownership is growing rapidly around the world. According to ITU (International 572 
Telecommunication Union, Geneva), in 2015, there were more than 7 billion mobile telephone 573 
subscriptions across the world, over 70% of which were in low- or middle-income countries (101). 574 
However, in these countries, smartphone use is still much more among the young and educated 575 
(https://www.pewglobal.org/2019/02/05/smartphone-ownership-is-growing-rapidly-around-the-world-but-576 
not-always-equally/).  577 
WHO recognizes the significant role that digital technologies can play in strengthening the health system  578 
in countries to achieve universal health coverage, th  health-related Sustainable Development Goals and 579 
other health objectives. In 2018, 121 countries had n tional eHealth strategies, representing the beginning 580 
of a shift from an unsustainable project-based approach towards a systematic, integrated approach designed 581 
for cost-effective investment and alignment of partne s (102). The joint WHO-ITU  initiative “Be He@lthy, 582 
Be Mobile” for the prevention and management of noncommunicable diseases, their comorbidities and 583 
their risk factors, including improving disease diagnosis and tracking, is of great importance. MASK is one 584 
of the examples of  the “Be He@lthy, Be Mobile” handbook on how to implement mBreatheFreely for 585 
asthma and COPD (103). 586 
Conclusion 587 
mHealth has the potential to profoundly impact healthc re (3). mHealth apps now represent an important 588 
evolution of health and care for AR since RWE has identified patients’ behaviours and practices and this 589 
will have a profound impact on current guidelines and care pathways. Rhinitis is not a severe disease but it590 
does have a major impact on social life, school and work productivity (104). Asthma-rhinitis 591 
multimorbidity plays a key role in understanding asthma and can be used as a model of multimorbidity. 592 
Moreover, asthma and rhinitis have a life course approach whereas most chronic diseases start early in life 593 
but are only clinically evident in adulthood. The revolution is underway for AR and asthma, and the lessons 594 
learnt are transposable to other chronic diseases and will design innovative health strategies and servic s as 595 
well as change management (105). 596 
 597 
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Table 1: Global applicability of mHealth Apps in allergic rhinitis (adapted from (13)) 
Applicability mHealth Apps 
Clinical 
practice 
Physicians will be able to read the files of the patients in order to: 
• Optimize treatment for the patient and, in particular, for the current or the next 
pollen season. 
• Assess and increase adherence to treatment. 
• Help in shared decision making. 
• Prescribe allergen immunotherapy (AIT) more rapidly when the patient is not 
controlled despite optimal pharmacologic treatment. 
• Determine the efficacy of any treatment including AIT . 
• Apps are an essential tool for providing personalized medicine in AR and asthma. 
Change 
management 
• Many patients are uncontrolled and non-adherent to treatment. Apps can 
indirectly assess and help (e.g., reminders) adherence. 
• Patients appear to use their medications as needed and not on a regular basis as 
prescribed 
• Change management is needed and may be facilitated by apps 
Patient 
empowerment 
• Better understanding of the symptoms 
• Sentinel network linking aerobiology data and control 
• Improved adherence 
• Self-management 
• Alert systems 
• Messages sent by the app. 
Clinical trials • To assess environmental control measures 
• To assess pharmacotherapy 
• For RCTs, it is essential to have clarity on definitions, and relevant tools. Apps 
allow 
• To better stratify the patients, in particular for AIT   
• To assess the efficacy of treatments during the trial 
• To assess the efficacy when the treatment is stopped 
• Feasibility of real-life studies  
• To confirm RCTs  




of medicines  
• Controlled trials designed with a uniform approach will be more easily evaluated 
by the Health Technology Assessment agencies (such as NICE) for 
reimbursement.   
• Better understanding of direct and indirect costs 
 • Controlled trials designed with a uniform approach will help to synchronize the 
data from real-life world regarding clinical effects and safety/tolerability of new 




• A uniform definition and a collaborative approach to epidemiological, genetic 
and mechanistic research are important and will be enhanced by the 
stratification of patients using apps.  
• Different levels of phenotype characterization (granularity) can be applied to 
assess phenotypic characterization in old age subjects.   
Epidemiology • In epidemiologic population studies, standardized definitions and tools are 
fundamental.  
• Apps may allow novel approaches combining classical cross-sectional and 
longitudinal studies with real life studies in large populations. 
Employers • AR and asthma represent a major burden for the employers, and the 
estimated annual costs in the EU range from 30 to 60 B€.  Better control of the 
disease was shown to reduce costs.  
• Apps have the potential to improve the control of allergic diseases and to 
significantly improve work productivity at the EU level. 
 
 
Table 2: Examples of mHealth apps for allergic rhinitis 
 






Multicountry      
 Air Matters X X  https://air-matters.com 
 AllergyMonitor X  X  
 Austria Pollen 
Information 
Service 
X  X www.pollenwarndienst.at 
 Breezometer X X  https://breezometer.com/products/pollen-api 
 The Weather 
Channel 
X   https://play.google.com/store/apps/details?id=com.weather.Weather 
 
 POLLEN & PHD X  X https://www.polleninfo.org, two separate but interlinked apps 
 MASK-air   X https://www.mask-air.com 
 Pollen alert 
Europe 




  X https://www.
mask-air.com 
Argentina Alerta Polen 
Argentina 
X   https://play.google.com/store/apps/details?id=com.mobillers.alertapolen&hl=e
s 
Australia Air Rater    https://airrater.org 
Denmark Dagens Pollental X   https://www.astma-allergi.dk/dagenspollental 
France ALK-Allergik    https://maviedallergik.fr/nos-services 
 Allergy Track    https://www.android-logiciels.fr/allergy-track/ 
 i-pollen    http://www.gammehumex.fr/lapplication-i-pollen/ 
 Plume Air Report    https://air.plumelabs.com/fr/ 
Germany Pollen App X  X http://www.pollenstiftung.de/ak 
Italy Pollen App X X  https://itunes.apple.com/it/app/polliniitalia/id621302844?mt=8 
  X X  https://www.ilpolline.it/i-calendari-pollinici 
 Allergy Control X X X https://itunes.apple.com/it/app/allergy-control/id973452501?mt=8 
 Allergy Monitor X  X https://play.google.com/store/apps/details?id=com.tpsproduction.allergymonit
or&hl=it 
 MeteoAllergie X   https://play.google.com/store/apps/details?id=com.dlsolutions.meteoallergie&
hl=it 
 Bollettino meteo 
Pollini e allergie 
in Italia 
X   https://www.3bmeteo.com/meteo/italia/pollini 




  X https://play.google.com/store/apps/details?id=com.wellnessandwireless.rapp 
NL  X   https://pollennieuws.nl/   
  X   https://hooikoortsradar.nl/ 
Poland e-allergy   X  
Portugal INSPIRERSMUNDI   X https://www.facebook.com/Projeto-Inspirers-218849795347948 
Spain INSPIRERSMUNDI   X https://www.facebook.com/Projeto-Inspirers-218849795347948 
 R-Alergo X   http://alergialafe.org/noticias/172-r-alergo 
 Polen Control X   https://www.seaic.org/inicio/polen-control 
 Niveles de Polen X   https://play.google.com/store/apps/details?id=es.diox.android.alergia&hl=es 
 Intolerapp X   https://socialmediatica.com/intolerapp-la-aplicacion-ideal-para-alergicos-e-
intolerantes-alimentarios/ 
 ALK Polen X   http://www.ticsalut.cat/observatori/es_apps/265/al-k-polen 
 Planttes X   http://www.planttes.com/ 
Switzerland AllyScience    https://allyscience.ch/ 
UK My Pollen 
forecast UK 
X   https://itunes.apple.com/gb/app/my-pollen-forecast-uk/id1244428929?mt=8 
 Piri X   http://www.piriallergy.com/pollen-count.html 
USA AcuPollen    http://www.nynjpollen.com 
 My Pollen 
Forecast 
X  X https://www.jrustonapps.com/apps/my-pollen-forecast 
 Plume Air Report X  X https://plumelabs.com/en/air/ 
 Poncho: wake up 
wheather 
X   https://www.crunchbase.com/apptopia_app/39a4271c-7286-4523-bed3-
7cecdf55e0bf 
 WeathterBug    https://www.weatherbug.com 
 
Table 3: The global MASK Good Practice and IT solution (modified from (62)) 
App (MASK-air) deployed in 23 countries: TRL9 (Technology Readiness level), Electronic clinical decision 
support system (ARIA e-CDSS): TRL 7, e-physician questionnaire deployed in 16 countries: TRL9. 
 
• App: 29,000 users, 23 countries, 17 languages 
• Tested with patients 
• GDPR including geolocation (17) 
• Good Practice of the EIP on AHA, follows CHRODIS (106) 
• Good Practice on digitally-enabled, integrated, patient-centred care endorsed by DG Santé (62) 
• Based on 11 EU grants (MeDALL (107), GA2LEN (108)) including - in 2018 - POLLAR (25), VIGOUR, 
DigitalHealthEurope, Euriphi (Digital transformation of health) and -in 2019- Gatekeeper 
• From a validated “research” tool (2004-2018) to large scale deployment (2019-) 
o Validation with COSMIN guidelines (109). 
o Baseline characteristics (110) 
o Work productivity (111, 112) 
o EQ-5D and WPAI-AS (113) 
o Novel phenotypes of allergic diseases (71) 
o Adherence to treatment (12, 85) 
o Novel approaches to inform the efficacy of treatment (12, 96) 
• Patient’s organizations and scientific societies involved 
• GARD (WHO alliance) 
• Presented during WHO and EU ministerial meetings (114, 115) 
• Next-generation care pathways meeting (Dec 3, 2018) with the EIP on AHA, POLLAR (EIT Health) and 
GARD 
• 51 MASK papers in 12 languages (116-119) 
• Dissemination according to the EIP on AHA (60) 
Transfer of innovation (TWINNING (120)) 
• Interoperable platform with MASK 
• 25 Reference Sites of the European Innovation Partnership on Active and Healthy Ageing plus Argentina, 
Australia, Brazil, Canada, Mexico (116-119) 
• 900 patients enrolled 
• GDPR solutions solved 
ARIA e-CDSS   
• Interoperable platform with MASK 
• Based on an expert meeting (97), and validation by Delphi questionnaire (69) and real-world evidence 
using MASK-air (12, 96) 
• Electronic version available (69) 
 
